Scott Shuttleworth
![](https://rogermontgomery.com/wp-content/uploads/2015/03/DH4_4191-ScottShuttleworth3-133x133.jpg)
You may be surprised that I’m asking this question; surely the answer is very trivial. Well, let’s take a look. Continue…
A reader asked me a question on my recent blog post on Nick Scali (ASX: NCK) and I thought I would make it the topic for today. The reader asked; “Is there a reason why the company would prefer to increase debt rather than fund with cash reserves?” Continue…
If I were to begin by saying that investments (at fair prices) in businesses with strong economics and long term sustainable competitive advantages have tended to yield better than average returns in the past, would I be saying something controversial? Well I guess that depends on where I say it… but on this blog at least it shouldn’t raise many eyebrows. Continue…
A recent IPO that we did not participate in was Monash IVF Group Limited (ASX: MVF). Whilst we appreciate the quality of the business, its staff and management, we believe that it perhaps may be on the expensive side and would prefer to seek more value before proceeding any further. Continue…
Any investor who has spent some time in the market will know the first day that a stock is listed can be a very interesting event. IPO days are known for big up moves and it’s almost surprising to see an IPO flop. To take a few examples, JB Hi Fi rallied 45 per cent on its first day of trading, Veda rallied 40 per cent on its first day and Beacon Lighting rallied 60 per cent on its first day – all very impressive! Continue…
Over the weekend I read a great article written by James Olsen of First Niagura Private Client Services. For those of you with access to ProQuest I would highly recommend that you read the full article there but for those of you without I have summarized the key points below. Continue…
Following yesterday’s article on Yo (found here) I was reminded of an article I read whilst studying investment analysis under Professor Robert Durand of the University of Western Australia (now at Curtin University). The article (which can be found here) titled “Contagious Speculation and a Cure for Cancer: A Nonevent that Made Stock Prices Soar” by Huberman and Regev, described the series of events surrounding the stock price of EntreMed (ENMD) and other biotech stocks listed in the United States. Continue…
In May 2014, Seek Limited (ASX: SEK) announced an intention to sell part of its stake in Zhaopin; the market leader of online recruitment services in China. Continue…
As I’m sure many of our readers are aware, The Reject Shop (ASX: TRS) announced yesterday a revised profit forecast for the financial year to June 2014 of $14.5 – $15.5 million, down around 15 per cent from the previous guidance of $17 – $18 million. The Reject Shop IS NOT a holding in The Montgomery Funds. Continue…
One stock that had excellent performance on its first day as a listed company was Beacon Lighting (ASX: BLX) which had its IPO in April of 2014 with a $142m valuation. Continue…